Is ANTH a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

880 people get ANTH articles and Market Currents by email alert.

Get email alerts on ANTH »

HEADLINES:

Anthera Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Mon, May 20
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results

PR Newswire (May 13, 2013)
Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study

PR Newswire (May 7, 2013)
Anthera Announces First Quarter 2013 Financial Report and Conference Call

PR Newswire (May 3, 2013)
Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility

PR Newswire (Apr 5, 2013)
Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod

PR Newswire (Mar 27, 2013)
Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results

PR Newswire (Mar 26, 2013)
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus

PR Newswire (Mar 22, 2013)
Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference

PR Newswire (Feb 7, 2013)
Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil

PR Newswire (Feb 5, 2013)
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock

PR Newswire (Jan 30, 2013)
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

PR Newswire (Jan 25, 2013)
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock

PR Newswire (Jan 24, 2013)
Anthera Shifts Its Strategy For Blisibimod
Brian L. Wilson • Wed, Jan 23 • 11 Comments
Anthera Pharmaceuticals Trading Higher On Additional Data; Need For Capital Could Cap Upside
PropThink • Thu, Nov 29, 2012 • 13 Comments
Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit

PR Newswire (Nov 28, 2012)
Anthera Recovering After Long Fall
Elias Simpson • Tue, Nov 27, 2012 • 7 Comments
Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

PR Newswire (Nov 20, 2012)
Anthera's Lupus Drug Gets Second Chance After Clinical Trial Disaster
Brian L. Wilson • Wed, Nov 14, 2012 • 2 Comments
Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting

PR Newswire (Nov 13, 2012)

To learn more about Seeking Alpha Pro, click here.

Anthera Shifts Its Strategy For Blisibimod
Brian L. Wilson • Wed, Jan 23 • 11 Comments
Anthera Pharmaceuticals Trading Higher On Additional Data; Need For Capital Could Cap Upside
PropThink • Thu, Nov 29, 2012 • 13 Comments
Anthera Recovering After Long Fall
Elias Simpson • Tue, Nov 27, 2012 • 7 Comments
Anthera's Lupus Drug Gets Second Chance After Clinical Trial Disaster
Brian L. Wilson • Wed, Nov 14, 2012 • 2 Comments
4 Reasons To Buy Anthera Pharmaceuticals
Jorge Aura • Mon, Jul 16, 2012 • 14 Comments
A Long Shot In The Lupus Market Gains Attention
Jessica King Holden • Fri, Jun 15, 2012 • 5 Comments
Lone IPO of the Week: Anthera Pharmaceuticals
SA Editor Abbi Adest • Tue, Feb 23, 2010 • 1 Comment

GlaxoSmithKline: Buy For 4.5% Yield
Cris Frangold • Mon, Oct 8, 2012 • 3 Comments
Pick Biotech Winners Like A Pro: John McCamant
Life Sciences Report • Fri, Oct 5, 2012 • 2 Comments
Was The HGSI Acquisition A Good Move For GlaxoSmithKline?
IncomeHunter • Tue, Aug 28, 2012 • 2 Comments
What's Driving Stocks Tuesday: ECB And Fed Hope And Fumes
Markos Kaminis • Tue, Aug 7, 2012 • 3 Comments
Hedge Funds Have Been Buying These Stocks Recently
Insider Monkey • Wed, Aug 1, 2012 • 4 Comments
Recent Noteworthy Institutional 5% Ownership Filings In Biotech
GuruFundPicks • Tue, Jul 17, 2012 • 1 Comment
Glaxo And Human Genome Have Apparently Seen Reason
Stephen Simpson • Mon, Jul 16, 2012
Binary Biotech Events And The Uselessness Of Analysts
NN Securities • Mon, Jul 16, 2012 • 11 Comments
3 Companies Poised For Big Moves
Jorge Aura • Wed, Jul 11, 2012 • 1 Comment
3 Pharma Companies With Minimal Debt To Consider At The Current Levels
Matt Schilling • Wed, Jul 11, 2012
3 Healthcare Companies With Insider Buys On June 29
Markus Aarnio • Tue, Jul 3, 2012
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, Jun 29, 2012 • 3 Comments
Will Human Genome End Up Blazing A Trail For Others?
Stephen Simpson • Mon, Apr 9, 2012 • 11 Comments
Biotech Class Of 2010: IPOs Revisited
Steven Breazzano • Wed, Jan 4, 2012 • 3 Comments
4 Rallying Healthcare Stocks Snapped Up By Company Insiders
Kapitall • Tue, Nov 15, 2011 • 3 Comments
8 Oversold Healthcare Stocks Being Bought Up By Insiders
Kapitall • Tue, Sep 20, 2011 • 1 Comment
10 Most Popular Drug Companies That Hedge Funds Love
Insider Monkey • Fri, Aug 26, 2011
8 Oversold Small Caps Insiders Are Buying
Kapitall • Wed, Aug 3, 2011
5 Small Caps Reporting Earnings This Week Being Bought by Insiders
Kapitall • Tue, Aug 2, 2011
7 Small-Cap Biotechs With Bullish Insider Buying in 2011
Zvi Bar • Sun, Jun 12, 2011 • 13 Comments

Anthera Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Mon, May 20
Anthera Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Oct 25, 2012

Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results

PR Newswire (May 13, 2013)
Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study

PR Newswire (May 7, 2013)
Anthera Announces First Quarter 2013 Financial Report and Conference Call

PR Newswire (May 3, 2013)
Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility

PR Newswire (Apr 5, 2013)
Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod

PR Newswire (Mar 27, 2013)
Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results

PR Newswire (Mar 26, 2013)
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus

PR Newswire (Mar 22, 2013)
Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference

PR Newswire (Feb 7, 2013)
Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil

PR Newswire (Feb 5, 2013)
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock

PR Newswire (Jan 30, 2013)
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

PR Newswire (Jan 25, 2013)
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock

PR Newswire (Jan 24, 2013)
Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit

PR Newswire (Nov 28, 2012)
Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

PR Newswire (Nov 20, 2012)
Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting

PR Newswire (Nov 13, 2012)
Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting

PR Newswire (Nov 1, 2012)
Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update

PR Newswire (Oct 24, 2012)
Anthera Announces Third Quarter 2012 Financial Report and Conference Call

PR Newswire (Oct 18, 2012)
Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)

PR Newswire (Sep 17, 2012)
Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update

PR Newswire (Aug 7, 2012)

ANTH vs. ETF Alternatives

Company Description

Currently, there's no company description for ANTH.

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, March 27, 4:33 PM Anthera Pharmaceuticals (ANTH) says it's initiated Phase 3 studies of blisibimod, for the treatment of systemic lupus erythematosus. Lupus is a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain and major organ complications. Shares -1.5% AH. Comment! [Healthcare, On the Move]
Tuesday, March 26, 4:46 PM More on Anthera Pharmaceuticals (ANTH): Q4 EPS loss beats on a per share basis as total sales jumped 85% Y/Y. Operating expenses declined, due primarily to the reduced clinical activity following the completion of its Pearl-SC study. Shares +1.6% AH. Comment! [Healthcare, On the Move, Earnings]
Tuesday, March 26, 4:26 PM Anthera Pharmaceuticals (ANTH): Q4 EPS of -$0.11 beats by $0.05. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, March 22, 12:19 PM Anthera Pharmaceuticals (ANTH +2.4%) gains after announcing earlier today that data from its Phase 2b Pearl-SC study will be presented at the 10th International Congress on Systemic Lupus Erythematosus on April 20. The presentation will be in the form of an abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus." Comment! [Healthcare, On the Move]
Tuesday, March 5, 2:01 PM Anthera Pharmaceuticals (ANTH +10.2%) gains today after Jefferies initiates coverage with a Buy rating and a $2 price target. Jefferies says that despite positive trial results for its lupus treatment, the stock trades at a discount to EV, and key interim catalysts over the next 12 - 18 months may turn out to be value drivers for the stock. 1 Comment [Healthcare, On the Move]
Friday, January 25, 8:06 AM Two other biotechs undertaking secondary offerings today: Arrowhead Research (ARWR) off 6.5% premarket - and Anthera Pharmaceuticals (ANTH) - off 10% premarket. (Arrowhead PR). (Anthera PR). (BG Medicine earlier). Comment! [Healthcare, On the Move]
Tuesday, November 6, 2012, 12:45 PM Midday top 10 gainers: NVGN +89%. FN +25%. ENOC +19%. ROSG +19%. WTW +18%. CSC +17%. ODP +17%. JIVE +16%. AOL +16%. ACAD +15%. Midday top 10 Losers: THQI -48%. SREV -37%. SYPR -35%. MKTG -30%. VVUS -23%. CDE -22%. CBM -22%. Z -19%. MMYT -18%. ANTH -17%. Comment!
Monday, November 5, 2012, 9:10 AM Premarket gainers: BMRN +28%. NTE +19%. NABI +12%. TRQ +10%. SOHU +9%. KBW +7%. ANTH +5%.
Losers: MTW -9%. RDN -9%. WYNN -6%. Comment! [On the Move]
Thursday, November 1, 2012, 4:02 PM Anthera Pharmaceuticals (ANTH +8%) moves higher after saying that an abstract of the results from its Phase 2b clinical study examining the treatment effect of blisibimod in systemic lupus erythematosus patients has been accepted as a late-breaking poster presentation at the 2012 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals. Comment! [Healthcare, On the Move]
Wednesday, September 19, 2012, 9:10 AM Premarket gainers: ACHN +12%. DCTH +9%. CPRX +9%. CBRL +7%. DRYS +7%. BVSN +6%. ANTH +6%.
Losers: IDIX -9%. GTAT -7%. 1 Comment [On the Move]
Tuesday, August 7, 2012, 5:42 PM More on Anthera Pharmaceuticals (ANTH): Q2 misses on the bottom line due to higher expenses. The company blames a higher cash burn during the second quarter, saying it was due the accelerated payments made that were previously slated for Q312. Comment! [Healthcare, Earnings]
Tuesday, August 7, 2012, 5:35 PM Anthera Pharmaceuticals (ANTH): Q2 EPS -$0.43 misses by $0.11. (PR) Comment! [Healthcare, Earnings]
Thursday, July 19, 2012, 9:10 AM Premarket gainers: MLNX +42%. SCSS +21%. GGC +16%. NOK +13%. WAG +11%. SWKS +10%. TXT +9%. EDU +8%. EBAY +8%. ALU +7%. QCOM +6%. PPG +5%. LUV +5%.
Losers: ANTH -15%. DCIX -15%. JCI -8%. CVS -6%. Comment! [On the Move]
Wednesday, July 18, 2012, 4:30 PM Anthera Pharmaceuticals (ANTH) announces [[plans to sell]] an undisclosed amount of common stock to be used for general corporate purposes. Piper Jaffray and Leerink Swann will acting as joint book-running managers in the offering. Shares -9.7% AH. Comment! [Healthcare, On the Move]
Tuesday, July 17, 2012, 11:40 AM Anthera Pharmaceuticals (ANTH +25%) continues to soar again today after saying that its final set of clinical data from Phase 2b PEARL-SC trials successfully met its primary endpoint in patients with systemic lupus erythematosus. The tests showed that sustained and greater treatment using PEARL-SC scored higher in the SELENA-SLEDAI disease-scoring index versus a placebo, and that patients reported longer periods between symptom flareups. Comment! [Healthcare, On the Move]
Tuesday, July 17, 2012, 9:10 AM Premarket gainers: DGIT +24%. PPHM +12%. JOEZ +10%. MAT +7%.
Losers: EDU -33%. ALU -18%. AUQ -8%. ANTH -7%. JBHT -5%. 1 Comment [On the Move]

Brisco88
$ANTH I thought this was suppose to take off !!
Jan 10, 3:58 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

pgaines72
just opened a position with ANTH. Anyone have any good articles regarding the company?
7/26/12
Reply (6)

• !Report Abuse
View all 6 replies
pgaines72: blisibimod in stage 2, possibly could have 2ndry use as anti inflammatory for cardiac patients, just lookin for articles. Happy investing.
7/26/12
• !Report Abuse
pgaines72: also, agree completely about numbers and charts but they don't cover everything, i.e secondary uses for drugs.
7/26/12
• !Report Abuse
Add a reply...

140 characters

santezero
long cluster: (200day 50day) (25.41, 68.19) RMTI GLUU AMRN LVLT VRUS GMCR STSI BPAX BIOS ANTH SIMO TNAV GTXI GLBC VITA PCRX MAKO
5/26/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

santezero
NASDAQ RMTI GLUU AMRN LVLT VRUS GMCR STSI BPAX BIOS ANTH SIMO TNAV GTXI GLBC VITA PCRX MAKO
5/26/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Asif Suria
Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing $ANTH
9/21/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

pgaines72
just opened a position with ANTH. Anyone have any good articles regarding the company?
7/26/12
Reply (6)

• !Report Abuse
View all 6 replies
pgaines72: blisibimod in stage 2, possibly could have 2ndry use as anti inflammatory for cardiac patients, just lookin for articles. Happy investing.
7/26/12
• !Report Abuse
pgaines72: also, agree completely about numbers and charts but they don't cover everything, i.e secondary uses for drugs.
7/26/12
• !Report Abuse
Add a reply...

140 characters

ANTH Anthera Pharmaceuticals, Inc.

ANTH

Anthera Pharmaceuticals, Inc.